Financial Performance - Operating revenue for the first nine months of 2023 was CNY 445,083,009.80, down 10.74% year-on-year[12] - Net profit attributable to shareholders for the first nine months of 2023 was CNY 103,319,227.37, a decline of 24.79% compared to the same period last year[12] - Basic earnings per share for the first nine months of 2023 decreased to CNY 0.2420, down 24.80% from CNY 0.3218 in the previous year[12] - Cash flow from operating activities for the first nine months of 2023 was CNY 110,327,988.09, a decrease of 23.17% year-on-year[12] - Total revenue for the period was 397,744,647.74, a slight decrease from 402,109,622.46 in the previous year[19] - Operating costs were 213,371,632.21, compared to 216,799,651.23 in the previous year, reflecting a decrease in expenses[19] - The net cash flow from investment activities decreased by 276.53% to -49,980,528.60, primarily due to reduced inflows from bank financial products[14] - The company reported a significant increase in trading financial assets, rising to CNY 116,274,068.49 from CNY 74,622,835.62, marking a growth of approximately 55.8%[74] - The company reported a financial income of CNY 10,785,997.77 for the first nine months of 2023, an increase from CNY 8,799,936.17 in 2022[83] Assets and Liabilities - Total assets as of September 30, 2023, amounted to CNY 1,288,585,209.69, a decrease of 0.35% compared to the end of 2022[12] - The company's asset-liability ratio (consolidated) improved to 8.51% from 10.55% at the end of 2022[12] - Accounts receivable increased by 250.43%, reaching CNY 8,178,331.61, primarily due to increased business settled by bills[13] - Contract liabilities decreased by 42.57% to CNY 5,786,142.19, attributed to a reduction in advance payments from customers[13] - Total liabilities as of September 30, 2023, were CNY 5,002,073.82, a decrease from CNY 6,019,985.13 at the end of 2022[80] - Shareholders' equity as of September 30, 2023, was CNY 755,035,010.05, down from CNY 830,324,306.90 at the end of 2022[80] Cash Flow - Cash and cash equivalents at the end of the period were 335,034,617.05, down from 339,223,548.70 in the previous year[19] - Cash received from investment activities decreased by 69.42% to 74,000,000.00, mainly due to fewer matured financial products being recovered[14] - The cash inflow from operating activities for the first nine months of 2023 is CNY 409,289,943.64, a decrease from CNY 433,190,969.91 in 2022, representing a decline of about 5.5%[89] - The net cash flow from operating activities decreased to ¥110,327,988.09 from ¥143,601,097.86, representing a decline of approximately 23%[91] - Cash inflow from investment activities totaled ¥76,265,336.98, down from ¥245,991,831.87, indicating a decrease of about 69%[91] Shareholder Information - Total outstanding shares at the end of the period were 426,918,340, with 99.9561% being freely tradable shares[21] - The largest shareholder, Jinghua Pharmaceutical Group Co., Ltd., holds 308,724,340 shares, representing 72.3146% of total shares[23] - The total number of common shareholders is 11,086[21] - The company has no litigation or arbitration matters during the reporting period[27] - There were no significant changes in the shareholding structure during the reporting period[23] Commitments and Governance - The company commits to stabilizing its stock price for three years after the public offering, initiating measures if the stock price falls below the audited net asset value per share[35] - The company has ongoing commitments related to avoiding competition and regulating related transactions, which are currently being fulfilled[32] - The controlling shareholder has made commitments to not interfere with the company's management or harm its interests[44] - The company will ensure that the remuneration system for directors is linked to the execution of compensation measures[45] - The company will provide supplementary or alternative commitments to protect the interests of shareholders and investors in case of unforeseen circumstances[63] Profit Distribution Policy - A profit distribution policy has been developed to enhance transparency and ensure stable returns for investors, with a focus on continuous and stable profit distribution[47] - The company plans to distribute profits primarily in cash, with a preference for cash dividends over stock dividends[49] - The company commits to a cash dividend distribution at least once per fiscal year, barring negative earnings or other special circumstances[49] - The company plans to distribute cash dividends of no less than 10% of the distributable profits achieved in the current year when conditions for cash dividends are met[51] - In the past three consecutive fiscal years, the cumulative cash dividends distributed by the company must not be less than 30% of the average annual distributable profits for those three years[51]

江苏森萱医药股份有限公司 证券代码:830946 证券简称:森萱医药 公告编号:2023-053 江苏森萱医药股份有限公司 关于接待机构投资者调研情况的公告 本公司及董事会全体成员保证公告内容的真实、准确和完整,没有虚假记载、 误导性陈述或者重大遗漏,并对其内容的真实性、准确性和完整性承担个别及连 带法律责任。 江苏森萱医药股份有限公司(以下简称"公司")于 2023 年 9 月 13 日接待 了 16 家机构的调研,现将主要情况公告如下: 一、 调研情况 调研时间:2023 年 9 月 13 日 调研形式:电话调研 调研机构:开源证券、谈水泉(北京)投资管理有限公司、聚鸣投资、嘉实 基金、上海勤辰私募基金管理合作企业(有限合伙)、进门财经、深圳市尚诚资 产管理有限责任公司、泰康资产管理有限公司、深圳市坤厚私募证券投资基金管 理有限公司、鸿运私募基金管理(海南)有限公司、宁波东玛私募基金管理有限 公司、杭州萧山泽泉投资管理有限公司、国泰基金、工银国际控股有限公司、深 圳中天汇富基金管理有限公司、华夏财富 上市公司接待人员:董事长吴玉祥,董事会秘书、财务负责人朱狮章 二、 调研的主要问题及公司回复概要 问题一: ...

江苏森萱医药股份有限公司 证券代码:830946 证券简称:森萱医药 公告编号:2023-052 江苏森萱医药股份有限公司 关于接待机构投资者调研情况的公告 本公司及董事会全体成员保证公告内容的真实、准确和完整,没有虚假 记载、误导性陈述或者重大遗漏,并对其内容的真实性、准确性和完整性承 担个别及连带法律责任。 江苏森萱医药股份有限公司(以下简称"公司")于 2023 年 9 月 12 日接 待了 2 家机构的调研,现将主要情况公告如下: 一、 调研情况 调研时间:2023 年 9 月 12 日 调研形式:网络调研 调研机构:天弘基金、开源证券 上市公司接待人员:董事长吴玉祥,董事会秘书、财务负责人朱狮章 二、 调研的主要问题及公司回复概要 问题一:请简单介绍一下公司上半年的经营情况 回复:公司在 8 月底公布了半年报,上半年度公司实现营业收入 3.18 亿, 同比下降 9.61%;实现归属于上市公司的净利润 7,663.22 万元,同比下降 19.82%;实现经营活动产生的现金流量净额 5,799.93 万元,同比下降 27.30%。 从主要经济指标看,公司上半年的经营业绩出现了一定程度的下滑,但总体平 稳 ...

江苏森萱医药股份有限公司 证券代码：830946 证券简称：森萱医药 公告编号：2023-049 江苏森萱医药股份有限公司 第三届董事会第二十一次会议决议公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连 带法律责任。 2.会议召开地点：公司会议室 3.会议召开方式：现场加通讯 4.发出董事会会议通知的时间和方式：2023 年 8 月 11 日以书面、邮件等方 式发出 5.会议主持人：吴玉祥 6.会议列席人员：公司监事、高级管理人员 7.召开情况合法、合规、合章程性说明： 本次会议的召集、召开符合《公司法》、《公司章程》的相关规定。 一、会议召开和出席情况 （一）会议召开情况 1.会议召开时间：2023 年 8 月 24 日 （二）会议出席情况 会议应出席董事 7 人，出席和授权出席董事 7 人。 董事袁拥军因出差以通讯方式参与表决。 董事姜春娟因出差以通讯方式参与表决。 董事任勇因出差以通讯方式参与表决。 二、议案审议情况 江苏森萱医药股份有限公司 （一）审议通过《关于审议<2023 年半年度报告>及<2023 ...

证券代码：830946 证券简称：森萱医药 公告编号：2023-050 江苏森萱医药股份有限公司 江苏森萱医药股份有限公司 （一）会议召开情况 1.会议召开时间：2023 年 8 月 24 日 2.会议召开地点：公司会议室 3.会议召开方式：现场加通讯 4.发出监事会会议通知的时间和方式：2023 年 8 月 11 日 以书面、邮件方式发 出 5.会议主持人：秦建 6.召开情况合法、合规、合章程性说明： 本次会议的召集、召开符合《公司法》、《公司章程》的相关规定。 （二）会议出席情况 （一）审议通过《关于审议<2023 年半年度报告>及<2023 年半年度报告摘要>的 议案 》 1.议案内容： 具体内容详见公司于同日在北京证券交易所信息披露平台 江苏森萱医药股份有限公司 三、备查文件目录 经与会监事确认签字并加盖监事会印章的《江苏森萱医药股份有限公司第三 届监事会第十九次会议决议》 江苏森萱医药股份有限公司 第三届监事会第十九次会议决议公告 本公司及监事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连 带法律责任。 一、会议召开和 ...

本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记 载、误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担 个别及连带法律责任。 江苏森萱医药股份有限公司2023年8月24日召开第三届董事会第二十一次会议。 我们作为公司独立董事，根据《中华人民共和国公司法》(以下简称"《公司法》") 《中华人民共和国证券法》《北京证券交易所股票上市规则(试行)》《北京证 江苏森萱医药股份有限公司 证券代码： 830946 证券简称：森萱医药 公告编号：2022-051 《公司章程》及公司《独立董事工作细则》等有关规定，本着审慎、负责任的态度， 基于独立判断，对公司第三届董事会第二十一次会议审议的相关事项发表独立意见 如下： 经审阅《关于审议<关于2023年1-6月募集资金存放与使用情况的专项报告> 的议案》，我们认为：公司2023年1-6月份对募集资金存放与使用，符合中国证 监会《上市公司监管指引第2号—上市公司募集资金管理和使用的监管要求》 (2022 年修订) 和《北京证券交易所股票上市规则(试行)》相关要求，决策程序 合法合规，不存在损害中小股东利益的情形。董事会审议该议案时，审议和表决 程序 ...

江苏森萱医药股份有限公司 募集资金存放与实际使用情况的专项报告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连 带法律责任。 江苏森萱医药股份有限公司 证券代码：830946 证券简称：森萱医药 公告编号：2023-048 一、募集资金基本情况 （一）2020 年公开发行募集资金基本情况 经中国证券监督管理委员会《关于核准江苏森萱医药股份有限公司向不特定 合格投资者公开发行股票的批复》（证监许可[2020]1302 号），核准公司向不特 定合格投资者公开发行不超过 9,000 万股新股，公司第三届董事会第二次会议在 股东大会的授权范围内确定最终发行股份为 6,000 万股，经询价后和主办券商开 源证券股份有限公司确定本次发行价格人民币 5.40 元/股，募集资金总额人民币 32,400.00 万元，公司募集资金扣除需支付的承销、保荐费用 2,106.00 万元后 的 30,294.00 万元已于 2020 年 7 月 16 日全部存入公司开立的江苏张家港农村商 业银行股份有限公司南通分行的 8020188800660 ...

Financial Performance - The company's operating revenue for the first half of 2023 was CNY 317,588,772.54, a decrease of 9.61% compared to CNY 351,367,667.65 in the same period last year[26]. - The net profit attributable to shareholders of the listed company was CNY 76,632,214.85, down 19.82% from CNY 95,570,133.06 year-on-year[26]. - The gross profit margin decreased to 42.98% from 47.02% in the previous year[26]. - The net profit for the period was ¥80.52 million, down 20.91% from ¥101.80 million in the previous year[48]. - The company reported a total revenue of CNY 262,682,698.06 from sales of goods and services in the first half of 2023, down from CNY 273,094,837.08 in the same period of 2022[179]. - The company reported a significant increase in trading financial assets, rising to CNY 141,152,369.86 from CNY 74,622,835.62, an increase of about 88.9%[164]. - The company reported a comprehensive income of $80,516,417.50 for the current period, compared to a lower figure in the previous period[187]. Assets and Liabilities - Total assets at the end of the reporting period were CNY 1,250,208,414.31, a decline of 3.32% from CNY 1,293,147,896.31 at the end of the previous year[27]. - Total liabilities decreased by 26.46% to CNY 100,302,125.15 from CNY 136,386,510.76 year-on-year[27]. - Cash and cash equivalents decreased by 22.30% to ¥375.33 million, accounting for 30.02% of total assets[43]. - Accounts receivable increased by 23.06% to ¥58.78 million, representing 4.70% of total assets[43]. - The total number of shares at the end of the period is 426,918,340, with 99.9561% being unrestricted shares[146]. Research and Development - R&D expenses decreased by 21.10% to ¥14.02 million, representing 4.41% of revenue[47]. - The company has 12 types of raw material drug technologies that are currently under evaluation for mass production, with the evaluation timeline being uncertain[93]. - The company plans to continue expanding its market presence and developing new products, as evidenced by the successful trial production of the formaldehyde slice project[7]. Environmental Compliance - The company adheres to environmental protection standards and regulations in its operations[64]. - The company has implemented various environmental protection standards including GB31571-2015 and GB37823-2019 for air and wastewater emissions[69]. - The company has not faced any administrative penalties related to environmental issues during the reporting period[88]. - The company has established a self-built sewage station for the treatment of combined industrial and domestic wastewater[76]. Shareholder Commitments - The company is currently fulfilling commitments related to stabilizing stock prices since May 19, 2020[105]. - The company has committed to a stable and continuous profit distribution policy, prioritizing cash dividends to enhance transparency and shareholder returns[124]. - The controlling shareholder has committed to not interfere with the company's management or misappropriate its interests[120]. - The company will ensure that any adjustments to the profit distribution policy are thoroughly justified and approved by the shareholders[124]. Risks and Challenges - The company faces tax policy risks due to potential loss of high-tech enterprise tax benefits, which could impact operations[91]. - Currency exchange rate fluctuations pose risks to the company’s export pricing and competitiveness, with measures in place to mitigate these risks[92]. - The company is increasing R&D investments to address market competition risks from both domestic and international players[92]. Operational Efficiency - The company has committed to enhancing management efficiency and controlling expenses to improve operational performance and profitability[118]. - The company plans to propose profit distribution or capital reserve conversion to stabilize stock prices if necessary[113]. - The company will establish a special account for the management of raised funds to ensure their proper and efficient use[119].

Financial Performance - Net profit attributable to shareholders for Q1 2023 was CNY 45,399,312.04, down 9.15% from CNY 49,972,953.24 in Q1 2022[9] - Operating revenue for Q1 2023 was CNY 175,152,565.78, a decrease of 4.08% compared to CNY 182,603,038.82 in the same period last year[9] - The net cash flow from operating activities decreased by 40.61% to CNY 24,748,327.96 from CNY 41,670,594.01 in the previous year[10] - Total operating revenue for Q1 2023 was CNY 175,152,565.78, a decrease from CNY 182,603,038.82 in Q1 2022, representing a decline of approximately 8.0%[75] - Net profit for Q1 2023 was CNY 47,662,270.56, down from CNY 53,340,658.13 in Q1 2022, reflecting a decrease of approximately 10.4%[76] - Earnings per share for Q1 2023 were CNY 0.1063, compared to CNY 0.1171 in Q1 2022, showing a decline of about 6.8%[76] Assets and Liabilities - Total assets as of March 31, 2023, reached CNY 1,316,040,144.93, an increase of 1.77% compared to the end of 2022[9] - The company's asset-liability ratio (consolidated) improved to 8.42% from 10.55% year-on-year[9] - The balance of accounts receivable increased by 276.28% to CNY 8,781,800 from the beginning of the year, mainly due to increased business settled by notes[11] - The balance of contract liabilities decreased by 52.14% to CNY 4,821,500, primarily due to a reduction in advance customer payments[11] - Total liabilities decreased to CNY 110,800,087.00 from CNY 136,386,510.76, indicating a decrease of approximately 18.7%[69] - The total equity attributable to shareholders increased to ¥1,132,562,063.11 from ¥1,086,641,028.20, marking a growth of approximately 4.2%[70] Cash Flow - Cash and cash equivalents decreased by CNY 1,611,400, with a net increase of cash and cash equivalents down 60.83% year-on-year[14] - The company reported a cash inflow from operating activities of CNY 114,578,823.47[19] - The net cash flow from operating activities for Q1 2023 was -2,620,049.16 CNY, compared to 154,984.76 CNY in Q1 2022, indicating a significant decline in operational cash generation[81] - Total cash inflow from operating activities in Q1 2023 was ¥140,961,929.11, compared to ¥147,707,932.11 in Q1 2022, a decline of approximately 4.6%[79] - Cash outflow for operating activities in Q1 2023 was ¥116,213,601.15, an increase from ¥106,037,338.10 in Q1 2022, representing an increase of about 9.9%[79] Shareholder Information - The total number of ordinary shares at the end of the period was 426,918,340, with 99.9561% being unrestricted shares[21] - The largest shareholder, Jinghua Pharmaceutical Group Co., Ltd., holds 72.3146% of the shares, totaling 308,724,340 shares[22] - The company has a stock price stabilization plan that will be activated if the stock price falls below the audited net asset value per share for 20 consecutive trading days[34] - The company plans to implement profit distribution or capital reserve conversion to stabilize stock prices if necessary, with a board meeting to be held within 5 trading days to discuss proposals[35] - Cash dividends will be distributed at a minimum of 10% of the annual distributable profit, with a cumulative minimum of 30% over any three consecutive years[48] Commitments and Compliance - The company has committed to a stable and continuous profit distribution policy, prioritizing cash dividends whenever possible[45] - The controlling shareholder has committed not to interfere with the company's management or harm its interests[43] - The company will comply with all relevant regulations regarding shareholding and changes, ensuring transparency in its operations[50] - The company guarantees the authenticity, accuracy, and completeness of its public offering application documents, and will bear legal responsibility for any false statements or omissions[54] - The company has pledged to hold a board or shareholder meeting within 10 working days to revise internal control systems to prevent participation in any fund pool business[62] Operational Efficiency - The company will enhance management efficiency and control costs to improve operational performance and profitability[41] - The company will establish a special account for the management of raised funds to ensure their proper use[42] - The company aims to accelerate the investment progress of fundraising projects to achieve expected benefits as soon as possible[42] - The company is focusing on research and development, with R&D expenses reported at CNY 5,774,630.02 in Q1 2022, down from CNY 8,037,579.41 in Q1 2021, suggesting a strategic shift in investment priorities[75]

Expansion and Approvals - In May 2022, the subsidiary Luhua Senxuan completed a 6,000-ton expansion project for Dioxane, passing safety acceptance[3]. - In August 2022, the subsidiary Nantong Company’s Pumice product received FDA approval for generic drug registration[3]. - By the end of 2022, the subsidiary Nantong Company had registered its raw material drug product Huberzong in 19 countries, with approvals from the UK, Portugal, Switzerland, and Spain[3]. - The subsidiary Nantong Senxuan was recognized as a "Specialized, Refined, and Innovative Small Giant Enterprise" in Jiangsu Province in December 2022[3]. - The company’s analysis and testing center laboratory received CNAS certification in December 2022[3]. Financial Performance - In 2022, the company's operating revenue reached approximately CNY 623.59 million, representing a 10.66% increase from CNY 563.54 million in 2021[26]. - The net profit attributable to shareholders increased by 22.29% to approximately CNY 160.54 million in 2022, compared to CNY 131.28 million in 2021[26]. - The gross profit margin for 2022 was 44.85%, slightly down from 44.87% in 2021[26]. - The company’s weighted average return on equity was 15.56% in 2022, up from 13.50% in 2021[26]. - The company’s basic earnings per share increased by 22.31% to CNY 0.3761 in 2022, compared to CNY 0.3075 in 2021[26]. Risks and Challenges - The company is facing risks related to tax policy changes, exchange rate fluctuations, and potential bad debts from accounts receivable due to rapid business expansion[10]. - The company’s procurement of raw materials has seen price increases, which could negatively impact profitability if the trend continues[10]. - The company has not listed the impact of the COVID-19 pandemic as a major risk for future operations, indicating a shift in focus[12]. - The company faced significant competition from raw material manufacturers in developing countries, particularly India, impacting pricing and market share[14]. - The company is at risk of market demand changes due to high technological barriers in the pharmaceutical industry, particularly from innovations in developed countries[14]. Research and Development - The company has been recognized as a high-tech enterprise and a specialized, refined, distinctive, and innovative enterprise at the provincial level[42]. - R&D expenditure for the current period amounted to ¥30,884,191.98, an increase from ¥28,102,839.63 in the previous period, representing a growth of approximately 10%[80]. - The total number of R&D personnel increased from 100 to 103, with the proportion of R&D staff to total employees remaining stable at around 15.77%[82]. - The company holds a total of 125 patents, up from 100 in the previous period, including 24 invention patents, an increase from 14[83]. - Several R&D projects have been completed, including the development of high-purity synthesis methods and cost-reduction techniques, aimed at enhancing product quality and market competitiveness[84]. Environmental Compliance - The company emphasized its commitment to environmental protection, with all subsidiaries complying with relevant pollution discharge standards and regulations[94]. - The company’s subsidiary, Jinghua Pharmaceutical Group Nantong Co., Ltd., reported a COD discharge concentration of 223.64 mg/l, which is below the regulatory limit of 500 mg/l[100]. - The company has implemented measures to protect the environment and improve living conditions for local residents[93]. - The company has established a rigorous monitoring frequency for various pollutants, including monthly checks for VOCs and quarterly checks for particulate matter[106]. - The company has not faced any administrative penalties related to environmental issues during the reporting period[115]. Shareholder Commitments and Financial Management - The company commits to stabilizing its stock price for three years after the public offering and listing on the selected tier, initiating measures if the stock price falls below the audited net asset value per share from the previous fiscal year for 20 consecutive trading days[153]. - The company will prioritize cash dividends in profit distribution, with a principle of distributing dividends at least once per fiscal year, barring special circumstances[168]. - The board will propose cash dividend plans based on the company's profitability and funding needs, ensuring that independent directors review and provide opinions on these plans[167]. - The company has a positive cumulative distributable profit and sufficient cash flow, allowing for cash dividends without affecting future operations[169]. - The company will ensure compliance with relevant laws and regulations regarding shareholding and changes in shareholding by its controlling shareholders[176].